Balance Sheet
Cash Flow Statement
Beginning Cash BalanceGains from Sales and Divestitures
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RedHill Biopharma (RDHL) Asset Writedowns and Impairment: 2017-2022

Historic Asset Writedowns and Impairment for RedHill Biopharma (RDHL) over the last 3 years, with Dec 2022 value amounting to $1.5 million.

  • RedHill Biopharma's Asset Writedowns and Impairment fell 85.88% to $1.5 million in Q4 2022 from the same period last year, while for Dec 2022 it was $6.0 million, marking a year-over-year decrease of 62.93%. This contributed to the annual value of $6.0 million for FY2022, which is 62.93% down from last year.
  • Latest data reveals that RedHill Biopharma reported Asset Writedowns and Impairment of $1.5 million as of Q4 2022, which was down 5.25% from $1.6 million recorded in Q3 2022.
  • Over the past 5 years, RedHill Biopharma's Asset Writedowns and Impairment peaked at $10.7 million during Q4 2021, and registered a low of $1.1 million during Q1 2020.
  • In the last 3 years, RedHill Biopharma's Asset Writedowns and Impairment had a median value of $1.8 million in 2020 and averaged $2.4 million.
  • Per our database at Business Quant, RedHill Biopharma's Asset Writedowns and Impairment surged by 417.28% in 2021 and then slumped by 85.88% in 2022.
  • Over the past 3 years, RedHill Biopharma's Asset Writedowns and Impairment (Quarterly) stood at $2.1 million in 2020, then skyrocketed by 417.28% to $10.7 million in 2021, then slumped by 85.88% to $1.5 million in 2022.
  • Its last three reported values are $1.5 million in Q4 2022, $1.6 million for Q3 2022, and $1.3 million during Q2 2022.